Michael DeGeorge Jr

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about….   👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers  

32

3 Comments

💥 SUPER MSL: The Quest to Become the TOP MSL on Your Team💥 Don't miss this weeks MSL Talk podcast with Daniel Snyder, Ph.D., Senior Medical Affairs & HEOR Leader who discusses the differentiators for MSLs that will make you stand out and become the top MSL on your team. Learn more about…. 👉 The qualities and differentiators of a “Super MSL” 👉 The skills and attributes that make MSLs stand out relative to their peers 👉 What common mistakes do MSLs need to avoid to 👉 What MSL Team leader should do to encourage and entice ideal MSL skills The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLtalk #careers

27

1 Comment

💥 Leveraging Real-World Evidence (RWE) in MSL Activities 💥 Don't miss this weeks MSL Talk Podcast with Elizabeth Pash, PhD, MS, RDN, Medical Affairs Executive Leader who shares insights on how to leverage real-world evidence (RWE) in MSL activities. This episode is sponsored by MSL Mastery, helping Medical Science Liaisons and aspiring MSLs to excel in their careers and lives through courses, coaching, and community. For more details, please visit MSLmastery (dot) com. In this episode, Beth discusses… 👉 What is Real World Evidence and how it is different from Clinical Trial Data 👉 How MSLs can effectively incorporate RWE into their discussions with healthcare professionals and key opinion leaders (KOLs) 👉 Challenges MSLs typically face when presenting RWE to stakeholders, and how can they overcome them 👉 Ways RWE can be used to enhance the strategic value of MSL activities 👉 Key skills MSLs need to develop in order to effectively understand and communicate RWE to diverse audiences The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #realworldevidence #careers

19

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL   Learn more about….   👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others   The MSL Talk Podcast will be available Tuesday May 14th, 2024 on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers  

15

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

15

2 Comments

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

14

5 Comments

When evaluating eIRB systems, be sure to consider the needs of ALL institutional stakeholders - not just the IRB users. Read our blog from Advarra expert Faith Bertrand, CIP for advice bon assessing and implementing these technologies.

5

In #NeurodegenerativeDisease news, specifically on an experimental treatment for #ALS, with this new #strategic partnership is penned between Dewpoint Therapeutics and Mitsubishi Tanabe Pharma America. ⚛️ The asset is the former's drug, designed "to address the accumulation of a protein into toxic structures that lead to neuronal dysfunction in people with ALS." 🤝 The alliance would grant MTP exclusive rights to license, upon achieving certain developmental milestones. ⚕️ This would add to MTP's existing US-marketed ALS treatment, #Radicava https://lnkd.in/evayrVv4' #Dewpoint #Mitsubishi #Pharma #Biopharma #Healthcare

6

Attention Life Science Professionals! 🔥 ANOTHER HOT TOPIC ALERT! 🧪🔬 Some More Good News in the Life Sciences! Check out the summary below regarding the 3,000 jobs created in Boston area in 2024. Share your thoughts in the comments! And if you are looking for folks, please let us know! hashtag #lifesciences #biotech #pharma #medicaldevice #diagnostics #hiring2024 #boston The Richmond Group USA

6

💥 Leveraging Real-World Evidence (RWE) in MSL Activities 💥 Check out this weeks MSL Talk Podcast with Elizabeth Pash, PhD, MS, RDN, Medical Affairs Executive Leader who shares insights on how to leverage real-world evidence (RWE) in MSL activities. This episode is sponsored by MSL Mastery, helping Medical Science Liaisons and aspiring MSLs to excel in their careers and lives through courses, coaching, and community. For more details, please visit MSLmastery (dot) com. In this episode, Beth discusses… 👉 What is Real World Evidence and how it is different from Clinical Trial Data 👉 How MSLs can effectively incorporate RWE into their discussions with healthcare professionals and key opinion leaders (KOLs) 👉 Challenges MSLs typically face when presenting RWE to stakeholders, and how can they overcome them 👉 Ways RWE can be used to enhance the strategic value of MSL activities 👉 Key skills MSLs need to develop in order to effectively understand and communicate RWE to diverse audiences The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #realworldevidence #careers    

35

8 Comments

💥 Leveraging Real-World Evidence (RWE) in MSL Activities 💥 Check out this weeks MSL Talk Podcast with Elizabeth Pash, PhD, MS, RDN, Medical Affairs Executive Leader who shares insights on how to leverage real-world evidence (RWE) in MSL activities. This episode is sponsored by MSL Mastery, helping Medical Science Liaisons and aspiring MSLs to excel in their careers and lives through courses, coaching, and community. For more details, please visit MSLmastery (dot) com. In this episode, Beth discusses… 👉 What is Real World Evidence and how it is different from Clinical Trial Data 👉 How MSLs can effectively incorporate RWE into their discussions with healthcare professionals and key opinion leaders (KOLs) 👉 Challenges MSLs typically face when presenting RWE to stakeholders, and how can they overcome them 👉 Ways RWE can be used to enhance the strategic value of MSL activities 👉 Key skills MSLs need to develop in order to effectively understand and communicate RWE to diverse audiences The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #realworldevidence #careers

19

1 Comment

💥 Top 5 MSL Frustrations and How to Overcome Them💥 The MSL Talk podcast is back after a 2 week long holiday break!! This weeks guests are Patrina Pellett, PhD, Medical Excellence Lead at MSL Mastery and Sarah Snyder, Medical Affairs Recruiter at The Carolan Group who discuss common frustrations faced by Medical Science Liaisons, exploring the top challenges and offering practical solutions. In this episode, we discuss… 👉 The top 5 most common MSL frustrations 👉 Practical ways to overcome field and personal challenges 👉 The importance of addressing self doubt and imposter syndrome This episode is sponsored by MSL Mastery, helping Medical Science Liaisons and aspiring MSLs to excel in their careers and lives through courses, coaching, and community. For more details, please visit MSLmastery (dot) com. The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.   MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #realworldevidence #careers

30

10 Comments

Looking forward to attending #ASH2024 this year. Let's connect and I can share with you how TD2 can support your next trial. 🔗https://hubs.li/Q02YXgqv0 #HematologyOncology #ClinicalTrials #OncologyCRO #BloodCancerResearch #DrugDevelopment #PrecisionOncology #ClinicalTrialSolutions

1

📨 Potential implications exist in regard to #LCM and #strategies regarding market exclusivity, see below, the latest from the FTC, sending warning letters to ten major pharma companies in an attempt to continue challenging and cracking down on #JunkPatents. 📂 The claims are around 'inaccurate or improper' patents in place which essentially block competition and keep drug prices high. Many big-name prescription brands are included in this round of probes. 2️⃣ 0️⃣ : "The FTC is challenging the patents of 20 different brand name products, claiming that their listings in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations—more commonly known as the Orange Book—are improper or inaccurate." 🤔 Are your brands affected? ❓ How might actions against you or your competitors affect your LCM strategy? https://lnkd.in/eVuapvWJ #LifeCycleManagement #RegulatoryAffairs #Policy #FTC #FederalTradeCommission #OrangeBook #PharmaPatents #AntiTrust #Pharma

1

🔍 Big Pharma's Marketing Spend: AbbVie Takes the Lead In a stunning revelation, pharmaceutical giant AbbVie has set a new record in healthcare provider marketing spend. According to recent data: • AbbVie spent a whopping $145.7 million on marketing to doctors in 2023 • This is the highest amount spent by any pharma company since reporting began in 2017 • For perspective, Pfizer spent $32 million and Merck $22 million in the same period What's driving this massive spend? 1. Post-Humira strategy: With its blockbuster drug Humira facing biosimilar competition, AbbVie is aggressively promoting other products 2. Key focus areas: - Vraylar (antidepressant): $28.1 million - Rinvoq (anti-inflammatory): $18.8 million - Botox: Over $15 million 3. Acquisition impact: The 2020 Allergan acquisition has significantly expanded AbbVie's portfolio and marketing efforts Is this level of spending Effective? What are your thoughts on the influence of pharma marketing on healthcare? #Pharma #Healthcare #Marketing #AbbVie #IndustryTrends

3

US HCPs: Dr. Suhail Dohad comments on the importance of an RCT in the PE clinical trial landscape. #LeadWithCAVT Rx only. Risk info: peninc.info/risk Clinical results may vary

116

A great day for patient access in ESRD! CMS Policy Update announced Monday November 25, 2024. Beginning in January 2025, CMMI’s Kidney Care Choices (KCC) value-based care model will carve out Transitional Drug Add-on Payment Adjustments (TDAPA payments) from financial calculations such as benchmarks, performance year expenditures and USPCC trend rates, allowing ESRD patients participating in a KCC to have increased access to certain innovative new drugs https://lnkd.in/gpFQ2RS6

72

2 Comments

Traditional PBMs recommend programs that steer to their own pharmacies because it benefits their bottom line. But if you as a plan sponsor think the PBM will help you defend those strategies when they come under scrutiny, I’ve got some bad news for you… Here’s a clickable super-cut of one Traditional PBM executive making it abundantly clear who he thinks is responsible for steerage: https://lnkd.in/e5FifjDG https://lnkd.in/emyECNKH https://lnkd.in/ezU7Vm3n https://lnkd.in/eXF3HUVJ PBMs are experts in ERISA. They understand that the plan sponsor ultimately ends up “holding the bag” on decisions like this, even when it was the PBM that recommended the strategy. This has massive implications for the legal risks that fiduciaries face in the current environment.

54

12 Comments